Anaphylaxis Checklists

ASCIA has developed checklists to assist in the management of patients with severe allergies who are at risk of anaphylaxis.

ASCIA Anaphylaxis Checklist for General Practice

Anaphylaxis Checklist for General Practice  

pdfAnaphylaxis Checklist for GPs168.68 KB  

ASCIA Anaphylaxis Checklist for Pharmacists

Anaphylaxis Checklist for Pharmacists

pdfAnaphylaxis Checklist for Pharmacists168.68 KB

Transitioning from Paediatric to Adult Care

Anaphylaxis Checklist: Transitioning from Paediatric to Adult Care for Young Adults with Severe Allergies

pdfAnaphylaxis Checklist: Transitioning from Paediatric to Adult Care for Young Adults with Severe Allergies205.88 KB 

Anaphylaxis Checklist for General Practice 

ASCIA Anaphylaxis Checklist for General Practice

The aim of this checklist to assist General Practitioners (GPs) to optimise management of patients with allergies who have had a severe allergic reaction (anaphylaxis) or are at risk of anaphylaxis.

  • Record history of the allergic reaction and suspected triggers using the ASCIA event record form.
  • Prescribe initial adrenaline (epinephrine) autoinjector for newly diagnosed patients and contact a specialist (allergy, respiratory, paediatrician), if necessary, for authority prescription, pending specialist appointment.
  • Inform patient/carer about patient support organisations, especially for newly diagnosed patients. Allergy & Anaphylaxis Australia or Allergy New Zealand
  • Refer patient to clinical immunology/allergy specialist and provide relevant clinical history. Specialists are listed on the ASCIA website.
  • For newly diagnosed patients or patients with adrenaline autoinjector/s that are due to expire or have been used, prescribe device/s and check that the dose is appropriate for the patient’s weight: 150 microgram devices for children weighing 7.5 to 20kg and 300 microgram devices for children weighing over 20kg and adults, including pregnant women. Two devices for children or adults are rebated by the PBS in Australia. No devices are currently rebated by Pharmac in New Zealand.
  • Complete and sign ASCIA Action Plan for Anaphylaxis (RED).The latest version is on the ASCIA website
  • Complete ASCIA Travel Plan if required
  • Inform patient that they should always carry their adrenaline autoinjector/s and ASCIA Action Plan.
  • Ensure the patient/carer understands that that adrenaline is the first line treatment for anaphylaxis and that antihistamines should not be used for the treatment for anaphylaxis. If antihistamines are used to treat mild to moderate allergic reactions, only non-sedating antihistamines should be used.
  • Educate patient/carer on how to give the adrenaline autoinjector (using trainer devices), recognition and treatment of allergic reactions, carrying and storage of the adrenaline autoinjector and appropriate allergen avoidance measures. For information go to
  • If patient has asthma, review and optimise asthma management and educate about asthma and anaphylaxis.
  • Inform patient/carer to check and note the expiry date of their autoinjector/s and inform the customer of expiry reminder clubs (e.g. EpiClub).
  • Encourage a GP appointment every 12 to 18 months, to prescribe new adrenaline autoinjector/s before they expire, to review if new allergies have developed or more severe allergic reactions have occurred, and to renew the patient’s ASCIA Action Plan for Anaphylaxis.

For adrenaline autoinjector supply updates check

© ASCIA 2020

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.
ASCIA resources are based on published literature and expert review, however, they are not intended to replace medical advice. The content of ASCIA resources is not influenced by any commercial organisations.
For more information go to
To donate to immunology/allergy research go to

Content updated March 2020 

Mod ASCIA Member
Donate to AIFA
go to NAS website
Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.